Amgen Agrees to Acquire Tularik
Turalik (TLRK ) agrees to be acquired by Amgen (AMGN ) in stock deal valued at $1.3 billion, or $25 per share. Amgen already owns about 20% of Tularik, which develops oral drugs that use gene regulation to treat cancer, immune disorders, and metabolic diseases. (3/29)
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.